alexa Simvastatin Induces Apoptosis Of Osteosarcoma Cells: A Novel Potential Therapeutic Approach
ISSN: 2471-8556

Oncology & Cancer Case Reports
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

December 05-07, 2016 Philadelphia, USA

Walied A Kamel, Eiji Sugihara, Sayaka Yamaguchi,Koichi Matsuo, Akihiro Muto, Hideyuki Saya, Takatsune Shimizu
Keio University, Japan
ScientificTracks Abstracts: Oncol Cancer Case Rep
DOI: 10.4172/2471-8556.C1.002
Osteosarcoma (OS) is the most common, non-hematopoietic, primary malignant bone tumor. Previously, we developed an OS mouse model by overexpressing c-MYC in bone marrow stromal cells derived from Ink4a/Arf knockout mice. We isolated highly tumorigenic cells (designated AXT cells) from tumors after serial transplantation. To obtain the novel candidate agents for OS, we performed drug screening and found that statins strongly suppressed AXT cell growth. Simvastatin treatment inhibited cell proliferation and induced apoptosis, which was almost fully rescued by the supplement of mevalonate and geranylgeranyl pyrophosphate but modestly by farnesyl pyrophosphate, suggesting that protein geranylgeranylation has a greater impact on OS cell viability. Simvastatin treatment inactivated RhoA through translocation of RhoA from membrane to cytosol and RhoA-GTP was accumulated by disruption of the interaction between RhoA and Rho-GDI. As a downstream signaling of RhoA, AMPK-p38MAPK pathway was strongly activated by simvastatin treatment, with AMPK functioning as an upstream effector of p38MAPK. Inhibition of AMPK or p38MAPK activation rescued apoptosis induced by simvastatin treatment, indicating that simvastatin exerts antitumor activity in OS via activation of AMPK- p38 MAPK pathway. Although treatment with simvastatin alone did not inhibit OS tumor growth in vivo, its combination with a fat-free diet induced a significant antitumor effect that was further enhanced by metformin administration. These findings suggest that the activation of AMPK- p38 MAPK pathway by statins become a potential therapeutic option for OS.

Walied kamel, 32 years old, a PHD student at keio unviersity, school of medicine, Tokyo, Japan.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version